Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 17,351

Document Document Title
WO/2018/132288A1
Compositions including derivatives of spinosyns of the following formulae and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-5,6 double...  
WO/2018/127801A1
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infect...  
WO/2018/127800A1
Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infect...  
WO/2018/125867A1
The disclosure relates to compounds and compositions that inhibit NFKB and are useful in the treatment of hematological malignancies such as lymphoma and myeloma.The present disclosure also provides methods for inhibiting growth and prol...  
WO/2018/124750A1
Provided in the present invention are: a compound of chemical formula 1; and an organic light-emitting element comprising the same.  
WO/2018/122664A1
A novel compound and a light-emitting element with high emission efficiency and a long lifetime are provided. The novel compound includes a benzofuropyrazine skeleton or a benzothienopyrazine skeleton, and each of a benzene ring and a py...  
WO/2018/124179A1
The present invention provides a compound represented by general formula (I) (in the formula, X is as described in the description and claims) or a pharmacologically acceptable salt thereof, and provides a pharmaceutical composition cont...  
WO/2018/119208A1
The present disclosure provides certain angular tricyclic compounds that are histone methyltransi erases G9a and/or GLP inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of G9a and/or GLP such as c...  
WO/2018/114710A1
The present application relates to new coumarin compounds and their uses as fluorescent labels. The compounds may be used as fluorescent labels for nucleotides in nucleic acid sequencing applications.  
WO/2018/119036A1
Disclosed are compounds, compositions and methods for treating of diseases, syndromes, conditions, and disorders that are affected by the modulation of MALT1. Such compounds are represented by Formula (I) wherein R1, R2, R3, R4, R5, R6, ...  
WO/2018/113538A1
The present invention relates to an organic compound with homobenzene as a core and the use thereof in an OLED device. The compound of the present invention has a higher glass transition temperature, a higher molecular heat stability, ap...  
WO/2018/118842A1
The present disclosure relates to amine-substituted heterocyclic compounds. The present disclosure also relates to pharmaceutical compositions containing these compounds and methods of treating a disorder (e.g., cancer) via inhibition of...  
WO/2018/117152A1
The purpose of the present invention is to provide: a method for producing a 7H-pyrrolo[2,3-d]pyrimidine derivative which is useful as a Janus kinase (JAK) inhibitory agent; an intermediate of the same; and a method for producing the int...  
WO/2018/116072A1
The present invention relates to compounds of the general formula (1) wherein the variables are defined as given in the description and claims. The invention further relates to uses of and to, processes and intermediates related to compo...  
WO/2018/108231A1
The present invention relates to novel pyrazoloazepin-8-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.  
WO/2018/111803A1
The present invention encompasses compounds of the formula (I) wherein the variables are defined herein which are suitable for the modulation of RORγ and the treatment of diseases related to the modulation of RORγ. The present inventio...  
WO/2018/110930A1
The present disclosure relates to an organic electroluminescent compound and an organic electroluminescent device comprising the same. The organic electroluminescent compound of the present disclosure has a high glass transition temperat...  
WO/2018/108230A1
The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents in the treatment of inflammatory diseases and conditions.  
WO/2018/108910A1
The present invention relates to novel substituted pyrazoloazepin-4-ones with phosphodiesterase inhibitory activity, as well as to their use as therapeutic agents the treatment of inflammatory diseases and conditions.  
WO/2018/112094A1
The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, X, R2, R2', R3, R4, R5, R6, and R7 of Formula I are def...  
WO/2018/108079A1
The present invention relates to a compound as represented by formula (I) or a pharmaceutically acceptable salt and stereoisomer thereof, wherein R1, R2, X, Y, P, W, and Ar are as defined in the description. The compound of formula (I) o...  
WO/2018/106641A1
The invention relates to triazole compounds of formula (I) or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: The invention also provides pharmaceutically acceptable compositions comprising the ...  
WO/2018/106646A1
The invention relates to triazole compounds of formula (I') or pharmaceutically acceptable salts thereof, useful as modulators of demyelinating diseases: wherein A is selected from the group consisting of (i), (ii), (iii), (iv), (v), and...  
WO/2018/102885A1
The present invention relates generally to chemical compounds and methods for their use and preparation in relation to the treatment of diseases, disorders or conditions which would benefit from the modulation of the alpha 7 nicotinic ac...  
WO/2018/104305A1
Substituted aromatic sulfonamides of formula (I) which are antagonists or negative allosteric modulators of P2X4, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds for manufacturing a ph...  
WO/2018/104194A1
The invention relates to compounds of formula (1) which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2018/104193A1
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.  
WO/2018/102315A1
Disclosed are crystalline forms of sepiapterin free base selected from polymorphs A, B, C, D, E, F, and G, and combinations thereof, as well as crystalline polymorphs of salts of sepiapterin. Also disclosed are pharmaceutical composition...  
WO/2018/102384A1
The present disclosure relates to compounds that are CaM Kinase inhibitors and to their use in the treatment of various disease states, including atrial fibrillation and myocardial infarction. In particular embodiments, the general struc...  
WO/2018/100070A1
The invention provides novel compounds having the general formula I: (I) wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.  
WO/2018/102325A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This inve...  
WO/2018/100029A1
The invention relates to heterocyclic compounds, particularly for use in electronic devices. The invention further relates to a method for producing the compounds according to the invention, and to electronic devices comprising same.  
WO/2018/095353A1
Provided are salts of aminoquinazoline derivative, pharmaceutical compositions containing the salts or a combination thereof, and uses of the salts or the pharmaceutical compositions in the manufacture of a medicament for the treatment a...  
WO/2018/097162A1
Provided is a novel compound or salt thereof which inhibits MTHFD2 and is useful for the treatment of diseases caused by MTHFD2 hyperfunction, the treatment of diseases related to MTHFD2 hyperfunction, and/or the treatment of diseases ac...  
WO/2018/095422A1
Provided in the present invention are a di-substituted maleic amide linker conjugated to an antibody and a preparation method and use thereof. In particular, the present invention conjugates a strongly cytotoxic active substance to a bio...  
WO/2018/089353A1
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are antagonists to αν- con...  
WO/2018/088665A2
The present invention relates to a compound for an organic optoelectric device represented by chemical formula 1, an organic optoelectric device employing the same, and a display device. Details of said chemical formula 1 are as defined ...  
WO/2018/083053A1
The present invention relates to fluoranthenyl-amine compounds according to a formula (I). Said compounds are suitable for use in electronic devices. The invention also relates to a method for producing said compounds, and to electronic ...  
WO/2018/083171A1
The invention relates to heterocyclic compounds of formula (I) as SIP modulators, pharmaceutical compositions comprising such compounds, and uses thereof in the treatment or alleviation of diseases or disorders mediated by an SIP receptor.  
WO/2018/083247A1
The present invention relates to 4,4a,5,7-tetrahydro-3H-furo[3,4-b]pyridinyl compound inhibitors of beta-site APP-cleaving enzyme having the structure shown in Formula (I) wherein the radicals are as defined in the specification. The inv...  
WO/2018/082962A1
Process for preparation of tetrahydrothiophene derivatives The present invention relates to a process for preparation of tetrahydrothiophene derivatives of formula I, (I) wherein the variables have the meanings as defined in the specific...  
WO/2018/085367A1
Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.  
WO/2018/081612A1
Substituted hydrazone compounds, methods of making such compounds and metal complexes thereof, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds and metal complexes to treat, preve...  
WO/2018/080126A1
The present invention provides a heterocyclic compound having a novel structure, and an organic light-emitting device comprising same.  
WO/2018/080068A1
The present invention relates to a novel compound and an organic electroluminescent device comprising same. The compound according to the present invention is used in an organic layer of an organic electroluminescent device, preferably a...  
WO/2018/079629A1
The present invention provides a novel 2,4,6-substituted pyrimidine derivative, which is a compound represented by formula (I) (in the formula, ring A is a 6-membered heteroaryl group having at least one N atom optionally substituted wit...  
WO/2018/079459A1
This organic electroluminescence element includes, in the order given, the following: a positive electrode; a plurality of organic functional layers including a light-emitting layer; and a negative electrode. The organic functional layer...  
WO/2018/081091A1
The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for inhibiting the activity of SHP2 phosphatase with the compounds and compositions of the invention. The present invention further rel...  
WO/2018/079759A1
The present invention provides a compound having a TrkA inhibitory activity or a pharmaceutically acceptable salt of the compound. The present invention relates to: a compound represented by formula (I) or a pharmaceutically acceptable s...  
WO/2018/078360A1
There are described compounds of formula (I): and there use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the of the hedgehog pathway, such as cancer, fibrosis and chronic graft-versus...  

Matches 1 - 50 out of 17,351